Pfizer (PFE) announced top-line data from a Phase 3 clinical trial, S-TRAC, evaluating SUTENT (sunitinib malate) capsules for the adjuvant treatment of renal cell carcinoma (RCC) patients at high risk for recurrence after surgery showed treatment with SUTENT statistically significantly improved disease-free survival (DFS) compared to placebo at month 36. S-TRAC is the first RCC study of a tyrosine kinase inhibitor (TKI) to prolong DFS in the adjuvant (administered after initial therapy) setting. The aim of adjuvant treatment is to help lower the risk of cancer recurrence in patients with early-stage cancer.